How do the macro trends impact Consumer & Retail and what are the implications for deal making and capital raising? Read about our takeaways from the ICR Conference 2023.

2022 was a turbulent year for the healthcare and biotech sectors. Mizuho’s Equity Capital Markets team reflects on the macro headwinds, liquidity crunch, and their expectations for 2023.

It was an eventful 2022 with equities suffering their worst year since the 2008 Financial Crisis. Andy Laszlo takes us through the markets and shares some thoughts on what’s ahead.

Senior Fintech Equity Research Analyst Dan Dolev answers questions about crypto and the fintech industry.

What is the ERG experience at Mizuho? Watch as members of M-WIN, PRIDE, MADE, MAAP, and UNIDOS talk about why they joined.

Investors have historically found the healthcare sector attractive during times of economic uncertainty. After all, we need access to healthcare solutions regardless of macroeconomic conditions. Still, not all healthcare stocks are the same, and Senior Equity Research Analyst Anthony Petrone believes that medtech might offer greater resilience compared to other stocks.

This quarter, Mizuho’s Equity Capital Markets team looks at the external macro forces affecting the biotech and healthcare sector, state of volatility and risk-off sentiment and how convertibles are holding up in the space.

Head of TMT ECM & SPAC Origination Andy Laszlo examines TMT issuance and breaks down the themes for the quarter.

The last few years have been a whirlwind, and those hoping for calm going forward may be sorely disappointed. Michal Katz, Head of Investment and Corporate Banking at Mizuho Americas, explains why volatility may be the new normal.